Monday May 29th 2017

The selective anti‐IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A‐induced levels of IL6 in human astrocytes

The family of interleukin 17 receptors (IL17Rs), subtypes IL17RA‐IL17RE, is targeted by the group of pro‐inflammatory IL17 cytokines (IL17A‐F) and moreover the newly developed anti‐IL17A antibody secukinumab (AIN457) has shown promise in Phase II trials in multiple sclerosis. Here, we show that human astrocytes, isolated from a fetal cerebral cortex, express IL17RA and IL17RC and in vitro treatment with IL17A increases protein levels of IL6 in human astrocytes, which is enhanced in the presence of TNFα, as determined by homogeneous time resolved fluorescence. Studies on acutely isolated mouse astrocytes are comparable to human astrocytes although the protein levels of IL6 are lower in mouse astrocytes, which also show a lower response to IL17F and IL1β in promoting IL6 levels. In…

This article: 

The selective anti‐IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A‐induced levels of IL6 in human astrocytes

Leave a Comment

More from category

Revisions Underway to McDonald Criteria on MS Diagnosis Revisions Underway to McDonald Criteria on MS Diagnosis
Revisions Underway to McDonald Criteria on MS Diagnosis Revisions Underway to McDonald Criteria on MS Diagnosis

An expert panel is tackling the first revision to the multiple sclerosis diagnostic criteria in 7 years. Among proposed [Read More]

Connecticut State Budget Call to Action
Connecticut State Budget Call to Action

/About-the-Society/News/Connecticut-State-Budget-Call-to-Action [Read More]

A Surge of New Drug Data in Multiple Sclerosis A Surge of New Drug Data in Multiple Sclerosis
A Surge of New Drug Data in Multiple Sclerosis A Surge of New Drug Data in Multiple Sclerosis

Medscape sits down with two neurologists to discuss advances in multiple sclerosis as presented at this year's American [Read More]

Progress on Bills to Address Step Therapy
Progress on Bills to Address Step Therapy

/About-the-Society/News/Progress-on-Bills-to-Address-Step-Therapy [Read More]

Brain Gadolinium Deposition Varies With Contrast Agent in MS Brain Gadolinium Deposition Varies With Contrast Agent in MS
Brain Gadolinium Deposition Varies With Contrast Agent in MS Brain Gadolinium Deposition Varies With Contrast Agent in MS

Gadolinium accumulation in the brain is greater with linear GBCAs than with macrocyclics. Multiple sclerosis experts [Read More]